Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$28.37M$28.37Mderivedno prior Q4 2022 on file Net Income-$4.14M-$4.14MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$17,842,000+43.3% Operating Incomederived-$10,937,000N/M Operating Cash Flowderived-$6,258,000N/M Free Cash Flowderived-$6,263,000N/M Margins · derivedGross margin62.9%
Operating margin-38.6%
Net margin-14.6%
ended Dec 31, 2023 · filed Apr 15, 2024 · 106 d after period end